Advertisement
Screener

OCULAR THERAPEUTIX, INC (OCUL) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount

2.7 / 5 stars · 54/101 Roast Me

OCULAR THERAPEUTIX, INC Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount

OCULAR THERAPEUTIX, INC (OCUL) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 23.58 million shares for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-07.

Discontinued › Income Statement › Earnings Per Share

us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2024-08-07

  • OCULAR THERAPEUTIX, INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-06-30 was 23.58M shares, a 0.75% decline year-over-year.
  • OCULAR THERAPEUTIX, INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 23.91M shares, a 0.46% decline year-over-year.
  • OCULAR THERAPEUTIX, INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-09-30 was 17.96M shares, a 20.97% increase year-over-year.
  • OCULAR THERAPEUTIX, INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-06-30 was 23.76M shares, a 59.34% increase year-over-year.
  • OCULAR THERAPEUTIX, INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 17.76M shares, a 20.33% increase from fiscal 2022.
  • OCULAR THERAPEUTIX, INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 14.76M shares, a 35.00% increase from fiscal 2021.
  • OCULAR THERAPEUTIX, INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2021 was 10.93M shares, a 26.63% decline from fiscal 2020.
  • OCULAR THERAPEUTIX, INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2020 was 14.90M shares, a 8.71% increase from fiscal 2019.
Period endAntidilutive Securities Excluded from Computation of Earnings Per Share, AmountAntidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 monthAntidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filedAntidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 monthAntidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 monthAntidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month
2024-06-3023.58M shares
10-Q · filed 2024-08-07		23.58M shares
10-Q · filed 2024-08-07
2024-03-3123.91M shares
10-Q · filed 2024-05-07
2023-12-3117.76M shares
10-K · filed 2024-03-11
2023-09-3017.96M shares
10-Q · filed 2023-11-07		17.96M shares
10-Q · filed 2023-11-07
2023-06-3023.76M shares
10-Q · filed 2024-08-07		23.76M shares
10-Q · filed 2024-08-07
2023-03-3124.02M shares
10-Q · filed 2024-05-07
2022-12-3114.76M shares
10-K · filed 2024-03-11
2022-09-3014.85M shares
10-Q · filed 2023-11-07		14.85M shares
10-Q · filed 2023-11-07
2022-06-3014.91M shares
10-Q · filed 2023-08-07		14.91M shares
10-Q · filed 2023-08-07
2022-03-3114.54M shares
10-Q · filed 2023-05-08
2021-12-3110.93M shares
10-K · filed 2024-03-11
2021-09-303.23M shares
10-Q · filed 2022-11-07		10.95M shares
10-Q · filed 2022-11-07
2021-06-3011.05M shares
10-Q · filed 2021-08-09		11.05M shares
10-Q · filed 2022-08-08
2021-03-313.00M shares
10-Q · filed 2022-05-09
2020-12-3114.90M shares
10-K · filed 2023-03-06
2020-09-308.99M shares
10-Q · filed 2021-11-08		8.99M shares
10-Q · filed 2021-11-08
2020-06-309.29M shares
10-Q · filed 2021-08-09
2020-03-3115.08M shares
10-Q · filed 2021-05-05		9.31M shares
10-Q · filed 2020-05-08
2019-12-3113.71M shares
10-K · filed 2022-02-28
2019-09-307.64M shares
10-Q · filed 2019-11-12		7.64M shares
10-Q · filed 2020-11-05
2019-06-307.63M shares
10-Q · filed 2020-08-07
2019-03-317.32M shares
10-Q · filed 2020-05-08
2018-12-315.25M shares
10-K · filed 2020-03-12
2018-09-305.19M shares
10-Q · filed 2019-11-12		5.19M shares
10-Q · filed 2018-11-07
2018-06-305.21M shares
10-Q · filed 2019-08-07
2018-03-315.08M shares
10-Q · filed 2019-05-10
2017-12-314.02M shares
10-K · filed 2020-03-12
2017-09-304.13M shares
10-Q · filed 2018-11-07
2017-06-304.68M shares
10-Q · filed 2018-08-07
2017-03-314.23M shares
10-Q · filed 2018-05-08
2016-12-313.11M shares
10-K · filed 2019-03-07
2016-09-302.99M shares
10-Q · filed 2017-11-07
2016-06-303.03M shares
10-Q · filed 2017-08-08
2016-03-312.98M shares
10-Q · filed 2017-05-05
2015-12-312.13M shares
10-K · filed 2018-03-08
2015-09-302.13M shares
10-Q · filed 2016-11-09
2015-06-302.13M shares
10-Q · filed 2016-08-09
2015-03-312.19M shares
10-Q · filed 2016-05-10
2014-12-311.73M shares
10-K · filed 2017-03-10
2014-09-301.76M shares
10-Q · filed 2015-11-10
2014-06-3014.18M shares
10-Q · filed 2015-08-10
2014-03-3114.01M shares
10-Q · filed 2015-05-15
2013-12-3113.42M shares
10-K · filed 2016-03-10
2013-09-3013.46M shares
10-Q · filed 2014-11-12
2013-06-3013.47M shares
10-Q · filed 2014-08-29
2012-12-3112.04M shares
10-K · filed 2015-03-20

Similar stocks

Stock NameCountryMarket CapPE Ratio
Prestige Consumer Healthcare Inc. (PBH)United States$2.163B13.03
Bausch Health Companies Inc. (BHC)$2.113B-1.68
Aurinia Pharmaceuticals Inc. (AUPH)$2.207B7.18
Braveheart Bio, Inc. (BRVE)United States$2.106B
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
Zai Lab Ltd (ZLAB)$2.241B-113.34
Generate Biomedicines, Inc. (GENB)United States$2.052B
PERRIGO Co plc (PRGO)Ireland$2.038B-0.79
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05
Advertisement